You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The collaboration will use AI to determine if patients can be grouped based on diagnostic test information, potentially leading to quicker and better diagnoses and treatments.
Siemens plans to offer 150 million shares, including 19.6 million shares to cover any overallotment, at between €26 to €31 per share.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
The firms are collaborating to develop a solution that includes Nightingale's nuclear magnetic resonance assay and PerkinElmer's sequencing services.
The device is an electrochemical lateral flow immunosensor test that will initially be used to detect dengue hemorrhagic fever, and later, to assess stroke severity.
The companies will work together to develop a series of cancer screening tests that employ Preora's cytology platform and its sample-preparation technologies.
The collaboration aims to eliminate barriers to testing for chronic kidney disease by standardizing the method for testing for the condition, thereby improving the comparison of test results between labs.
The test would also be used to detect antibiotic susceptibility. Fraunhofer received £900,000 from SBRI Healthcare in support of the project to develop the test.
The commission includes Shire, Microsoft, and EURODIS Rare Diseases Europe, and will develop a roadmap "to help the rare disease field ... shorten the multiyear diagnostic journey."
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.